Citation Tools
PDFRegular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response